Overview

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia
Phase:
Phase 2
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical